Literature DB >> 26270258

Nanodrug Formed by Coassembly of Dual Anticancer Drugs to Inhibit Cancer Cell Drug Resistance.

Yuanyuan Zhao1, Fei Chen1,2, Yuanming Pan1, Zhipeng Li1, Xiangdong Xue1,2, Chukwunweike Ikechukwu Okeke1,2, Yifeng Wang1,2, Chan Li1, Ling Peng3, Paul C Wang4, Xiaowei Ma1, Xing-Jie Liang1.   

Abstract

Carrier-free pure nanodrugs (PNDs) that are composed entirely of pharmaceutically active molecules are regarded as promising candidates to be the next generation of drug formulations and are mainly formulated from supramolecular self-assembly of drug molecules. It benefits from the efficient use of drug compounds with poor aqueous solubility and takes advantage of nanoscale drug delivery systems. Here, a type of all-in-one nanoparticle consisting of multiple drugs with enhanced synergistic antiproliferation efficiency against drug-resistant cancer cells has been created. To nanoparticulate the anticancer drugs, 10-hydroxycamptothecin (HCPT) and doxorubicin (DOX) were chosen as a typical model. The resulting HD nanoparticles (HD NPs) were formulated by a "green" and convenient self-assembling method, and the water-solubility of 10-hydroxycamptothecin (HCPT) was improved 50-fold after nanosizing by coassembly with DOX. The formation process was studied by observing the morphological changes at various reaction times and molar ratios of DOX to HCPT. Molecular dynamics (MD) simulations showed that DOX molecules tend to assemble around HCPT molecules through intermolecular forces. With the advantage of nanosizing, HD NPs could improve the intracellular drug retention of DOX to as much as 2-fold in drug-resistant cancer cells (MCF-7R). As a dual-drug-loaded nanoformulation, HD NPs effectively enhanced drug cytotoxicity to drug-resistant cancer cells. The combination of HCPT and DOX exhibited a synergistic effect as the nanosized HD NPs improved drug retention in drug-resistant cancer cells against P-gp efflux in MCF-7R cells. Furthermore, colony forming assays were applied to evaluate long-term inhibition of cancer cell proliferation, and these assays confirmed the greatly improved cytotoxicity of HD NPs in drug-resistant cells compared to free drugs.

Entities:  

Keywords:  assemble; carrier-free; drug resistance; insoluble drugs; pure nanodrug

Mesh:

Substances:

Year:  2015        PMID: 26270258      PMCID: PMC4712650          DOI: 10.1021/acsami.5b05347

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  37 in total

1.  Excited-state proton transfer reactions of 10-hydroxycamptothecin.

Authors:  Kyril M Solntsev; Erica N Sullivan; Laren M Tolbert; Shay Ashkenazi; Pavel Leiderman; Dan Huppert
Journal:  J Am Chem Soc       Date:  2004-10-06       Impact factor: 15.419

2.  Preparation and size control of sub-100 nm pure nanodrugs.

Authors:  Jinfeng Zhang; Yanan Li; Fei-Fei An; Xiaohong Zhang; Xianfeng Chen; Chun-Sing Lee
Journal:  Nano Lett       Date:  2014-12-18       Impact factor: 11.189

3.  Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.

Authors:  K B Tan; M R Mattern; W K Eng; F L McCabe; R K Johnson
Journal:  J Natl Cancer Inst       Date:  1989-11-15       Impact factor: 13.506

4.  EPR-effect: utilizing size-dependent nanoparticle delivery to solid tumors.

Authors:  Triantafyllos Stylianopoulos
Journal:  Ther Deliv       Date:  2013-04

5.  Carrier-free functionalized multidrug nanorods for synergistic cancer therapy.

Authors:  Mengjiao Zhou; Xiujuan Zhang; Yinlong Yang; Zhuang Liu; Baishun Tian; Jiansheng Jie; Xiaohong Zhang
Journal:  Biomaterials       Date:  2013-08-16       Impact factor: 12.479

6.  10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice.

Authors:  Leyang Zhang; Mi Yang; Qin Wang; Yuan Li; Rui Guo; Xiqun Jiang; Changzheng Yang; Baorui Liu
Journal:  J Control Release       Date:  2007-03-01       Impact factor: 9.776

7.  RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors.

Authors:  Zipeng Zhen; Wei Tang; Hongmin Chen; Xin Lin; Trever Todd; Geoffrey Wang; Taku Cowger; Xiaoyuan Chen; Jin Xie
Journal:  ACS Nano       Date:  2013-06-04       Impact factor: 15.881

8.  A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts.

Authors:  Mika Endo; Masanori Miwa; Masako Ura; Hiromi Tanimura; Kenji Taniguchi; Yoko Miyazaki; Jun Ohwada; Masao Tsukazaki; Satoshi Niizuma; Takeshi Murata; Sawako Ozawa; Hitomi Suda; Kotaro Ogawa; Eitaro Nanba; Shunsuke Nagao; Nobuo Shimma; Hisafumi Yamada-Okabe
Journal:  Cancer Chemother Pharmacol       Date:  2010-01       Impact factor: 3.333

9.  Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug.

Authors:  Xiaoyang Xu; Kun Xie; Xue-Qing Zhang; Eric M Pridgen; Ga Young Park; Danica S Cui; Jinjun Shi; Jun Wu; Philip W Kantoff; Stephen J Lippard; Robert Langer; Graham C Walker; Omid C Farokhzad
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-28       Impact factor: 11.205

Review 10.  Nanocrystal technology, drug delivery and clinical applications.

Authors:  Jens-Uwe A H Junghanns; Rainer H Müller
Journal:  Int J Nanomedicine       Date:  2008
View more
  19 in total

Review 1.  Nanoformulations for combination or cascade anticancer therapy.

Authors:  Lei Miao; Shutao Guo; C Michael Lin; Qi Liu; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

2.  Inhibition of glioblastoma growth and invasion by 125I brachytherapy in rat glioma model.

Authors:  Feihong Chen; Dan Wang
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

3.  Carrier-Free, Dual-Functional Nanorods Via Self-Assembly Of Pure Drug Molecules For Synergistic Chemo-Photodynamic Therapy.

Authors:  Yuping Zhao; Yanna Zhao; Qisan Ma; Bin Sun; Qingpeng Wang; Zhuang Ding; Huaizhen Zhang; Xiuling Chu; Min Liu; Zhengping Wang; Jun Han
Journal:  Int J Nanomedicine       Date:  2019-11-05

4.  A green approach to dual-drug nanoformulations with targeting and synergistic effects for cancer therapy.

Authors:  Shichao Wu; Xiangrui Yang; Yue Lu; Zhongxiong Fan; Yang Li; Yuan Jiang; Zhenqing Hou
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

5.  Preclinical Evaluation and Monitoring of the Therapeutic Response of a Dual Targeted Hyaluronic Acid Nanodrug.

Authors:  Minglong Chen; Wenqi Zhang; Kai Yuan; Mingxiang Bo; Bin Chen; Lu Li; Qingjie Ma; Lei Zhu; Shi Gao
Journal:  Contrast Media Mol Imaging       Date:  2017-07-11       Impact factor: 3.161

6.  Nanocrystals of a new camptothecin derivative WCN-21 enhance its solubility and efficacy.

Authors:  Jia You; Yuyuan Chen; Zubaeda M Mohamed Alsayeh; Xingyu Shen; Chun Li; Pengxuan Zhao; Fei Chen; Yingqian Liu; Chuanrui Xu
Journal:  Oncotarget       Date:  2017-05-02

7.  Surfactant Assisted Rapid-Release Liposomal Strategies Enhance the Antitumor Efficiency of Bufalin Derivative and Reduce Cardiotoxicity.

Authors:  Lina Gao; Lei Zhang; Fengjun He; Jing Chen; Meng Zhao; Simin Li; Hao Wu; Yumeng Liu; Yinan Zhang; Qineng Ping; Lihong Hu; Hongzhi Qiao
Journal:  Int J Nanomedicine       Date:  2021-05-25

8.  A facile route to form self-carried redox-responsive vorinostat nanodrug for effective solid tumor therapy.

Authors:  Leiqiang Han; Tianqi Wang; Jingliang Wu; Xiaolan Yin; Hao Fang; Na Zhang
Journal:  Int J Nanomedicine       Date:  2016-11-11

9.  Camptothecin-based nanodrug delivery systems.

Authors:  Yan Wen; Yingze Wang; Xiaoli Liu; Wei Zhang; Xinhe Xiong; Zhongxiao Han; Xingjie Liang
Journal:  Cancer Biol Med       Date:  2017-11       Impact factor: 4.248

10.  Facile Fabrication of Reduction-Responsive Supramolecular Nanoassemblies for Co-delivery of Doxorubicin and Sorafenib toward Hepatoma Cells.

Authors:  Qingqing Xiong; Mangmang Cui; Ge Yu; Jian Wang; Tianqiang Song
Journal:  Front Pharmacol       Date:  2018-02-06       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.